JLE

Hépato-Gastro & Oncologie Digestive

MENU

Impact of new immuno-oncological combinations on patient management and carte pathways in the treatment of hepatocellular carcinoma Volume 28, supplement 1, Avril 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

Tables

Author
1 CHU Bordeaux, Hôpital Haut-Lévêque, Service d’oncologie digestive, 33604 Pessac
2 INSERM U1053, BaRITOn, Université Victor Segalen, Bordeaux
* Correspondance

Systemic treatment of hepatocellular carcinoma (HCC) was dramatically modified by the advent of immunotherapy (atezolizumab) and anti-angiogenic (bevacizumab) combination in first line. Other combinations with immunotherapies could be validated in the near future. These new treatments are transforming the prognosis of the disease... but also the modalities of care pathways and the medical organization with a shift from oral treatments (out-patient consultation) to in-hospital intra-venous treatments. The purpose of this review is to describe the new care pathways, detailing the practical modalities of treatment choice, pre-treatment check-up, management of the treatment and its potential side effects. The role of the Hepato-Gastroenterologist in this new care pathway will remain central in close collaboration (and not in competition) with medical oncologists, since the more and more complex management of HCC requires obviously the association of hepatological and oncology skills.